Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
$5.30
-$0.58(-10.41%)
At close: 4:00 PM EST
$5.30
-$0.58(-10.41%)
Day’s Range― - ―
52-Week Range$2.02 - $11.41
Previous CloseN/A
Volume1.06M
Average Volume (3M)337.69K
Market Cap
$169.69M
Enterprise Value$134.75M
Total Cash (Recent Filing)$113.12M
Total Debt (Recent Filing)$78.00K
Price to Earnings (P/E)―
Beta2.77
Next Earnings
May 20, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding32,017,612
10 Day Avg. Volume334,695
30 Day Avg. Volume337,695
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)1.72
Price to Sales (P/S)0.00
P/FCF Ratio-4.19
Enterprise Value/Market Cap0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.37
Forecast
1Y Price Target
$26.00Price Target Upside390.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.66
Revenue Forecast (FY)$300.00K
Bulls Say, Bears Say
Bulls Say
Acne Pipeline PotentialThe next‑generation FASN inhibitor TVB‑3567 produced encouraging early pharmacokinetic results and includes an acne cohort to collect sebum pharmacodynamic data, which could speed dose selection and progression to later‑stage trials.
Liver Program Clinical AdvancementPositive phase 1 safety and pharmacokinetic data for the denifanstat–resmetirom combination support advancing into a phase 2 study using non‑invasive liver tests as primary endpoints, which could streamline enrollment and demonstrate early signals of efficacy.
Therapeutic DifferentiationFASN inhibition targets the root causes of acne rather than only reducing skin oil, making denifanstat a differentiated oral option that could attract dermatologist adoption and market share.
Bears Say
Analyst Conflict Of InterestDisclosure that the reporting firm does business with covered companies creates potential conflicts that could affect the perceived objectivity of analyst reports and investor confidence.
Financial Performance PressureA reported quarterly net loss combined with reduced research and administrative spending signals ongoing financial pressure that could constrain development timelines and strategic flexibility.
Financing RiskCurrent cash resources imply a limited runway and could necessitate additional financing to fully advance clinical programs, risking shareholder dilution if capital is raised.
Sagimet Biosciences, Inc. Class A News
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.02 and its highest was $11.41 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $169.69M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is May 20, 2026 which is in 37 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Mar 11, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.432 by $0.142.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.37.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 32,017,612 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.432. Following the earnings report the stock price went up 3.797%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.00 (390.57% Upside)
$26.00 (390.57% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 549.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $105.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 4.7%
Last 30 Days ▼ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
137.66%
12-Months-Change
Fundamentals
Return on Equity
-40.85%
Trailing 12-Months
Asset Growth
-27.32%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Stock 12 Month Forecast
Average Price Target
$26.00
▲(390.57% Upside)
Technical Analysis
Codexis
―
Cabaletta Bio
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
10.84% Insiders
6.02% Mutual Funds
23.61% Other Institutional Investors
54.56% Public Companies and Individual Investors